Caspase-3: A vulnerability factor and final effector in apoptotic death of dopaminergic neurons in Parkinson's disease
- Andreas Hartmann*,
- Stéphane Hunot*,
- Patrick P. Michel*,
- Marie-Paule Muriel*,
- Sheela Vyas†,
- Baptiste A. Faucheux*,
- Annick Mouatt-Prigent*,
- Hélène Turmel*,
- Anu Srinivasan‡,
- Merle Ruberg*,
- Gerard I. Evan†,
- Yves Agid*, and
- Etienne C. Hirsch*,§
- *Institut National de la Santé et de la Recherche Médicale U 289, Hôpital de la Salpêtrière, 47 Boulevard de l′Hôpital, 75013 Paris, France; †Imperial Cancer Research Fund Laboratories, 44 Lincoln's Inn Field, London WC2A 3PX, United Kingdom; and ‡IDUN Pharmaceuticals Inc., 11085 North Pines Road, La Jolla, CA 92037
-
Communicated by Jean-Pierre Changeux, Institut Pasteur, Paris, France (received for review August 20, 1999)
Abstract
Caspase-3 is an effector of apoptosis in experimental models of Parkinson's disease (PD). However, its potential role in the human pathology remains to be demonstrated. Using caspase-3 immunohistochemistry on the postmortem human brain, we observed a positive correlation between the degree of neuronal loss in dopaminergic (DA) cell groups affected in the mesencephalon of PD patients and the percentage of caspase-3-positive neurons in these cell groups in control subjects and a significant decrease of caspase-3-positive pigmented neurons in the substantia nigra pars compacta of PD patients compared with controls that also could be observed in an animal model of PD. This suggests that neurons expressing caspase-3 are more sensitive to the pathological process than those that do not express the protein. In addition, using an antibody raised against activated caspase-3, the percentage of active caspase-3-positive neurons among DA neurons was significantly higher in PD patients than in controls. Finally, electron microscopy analysis in the human brain and in vitro data suggest that caspase-3 activation precedes and is not a consequence of apoptotic cell death in PD.
Footnotes
-
↵ § To whom reprint requests should be addressed. E-mail: hirsch{at}ccr.jussieu.fr.
-
Article published online before print: Proc. Natl. Acad. Sci. USA, 10.1073/pnas.040556597.
-
Article and publication date are at www.pnas.org/cgi/doi/10.1073/pnas.040556597
- Abbreviations:
- CGS,
- central gray substance;
- DA,
- dopaminergic;
- MPP+,
- 1-methyl-4-phenylpyridinium;
- MPTP,
- 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine;
- PD,
- Parkinson's disease;
- TH,
- tyrosine hydroxylase;
- SNpc,
- substantia nigra pars compacta;
- VTA,
- ventral tegmental area
- Copyright © 2000, The National Academy of Sciences





